Mandate

Vinge has advised Vimian Group in connection with its rights issue

March 12, 2024

Vinge has advised Vimian Group AB (publ) in connection with a partly guaranteed rights issue which will provide Vimian with issue proceeds of SEK 1,633 billion before deduction of transaction costs.

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. At Vimian, one believes that every animal deserves the best available care. Vimian brings pioneering businesses together to make the market’s most innovative offerings accessible to more animal health professionals and pet owners.

Vinge’s team consisted of Dain Hård NevonenLinnéa Sellström, Anna Svensson, Michaela Ådén and Alexander Rüdén.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025